IDEXX Laboratories Inc. (IDXX)
IDEXX Laboratories Statistics
Share Statistics
IDEXX Laboratories has 81.33M shares outstanding. The number of shares has increased by -1.45% in one year.
| Shares Outstanding | 81.33M |
| Shares Change (YoY) | -1.45% |
| Shares Change (QoQ) | -0.51% |
| Owned by Institutions (%) | 87.22% |
| Shares Floating | 80.49M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 1.73M, so 2.11% of the outstanding shares have been sold short.
| Short Interest | 1.73M |
| Short % of Shares Out | 2.11% |
| Short % of Float | 2.13% |
| Short Ratio (days to cover) | 3.3 |
Valuation Ratios
The PE ratio is 38.33 and the forward PE ratio is 35.25. IDEXX Laboratories's PEG ratio is 6.29.
| PE Ratio | 38.33 |
| Forward PE | 35.25 |
| PS Ratio | 8.73 |
| Forward PS | 6.6 |
| PB Ratio | 21.33 |
| P/FCF Ratio | 42.64 |
| PEG Ratio | 6.29 |
Enterprise Valuation
IDEXX Laboratories Inc. has an Enterprise Value (EV) of 46.6B.
| EV / Earnings | 52.49 |
| EV / Sales | 11.96 |
| EV / EBITDA | 36.66 |
| EV / EBIT | 41.3 |
| EV / FCF | 58.39 |
Financial Position
The company has a current ratio of 1.31, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.31 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.17 |
| Total Debt / Capitalization | 14.27 |
| Cash Flow / Debt | 3.5 |
| Interest Coverage | 36.16 |
Financial Efficiency
Return on equity (ROE) is 0.56% and return on capital (ROIC) is 48.51%.
| Return on Equity (ROE) | 0.56% |
| Return on Assets (ROA) | 0.27% |
| Return on Capital (ROIC) | 48.51% |
| Revenue Per Employee | $354,318.55 |
| Profits Per Employee | $80,715.18 |
| Employee Count | 11,000 |
| Asset Turnover | 1.18 |
| Inventory Turnover | 3.98 |
Taxes
| Income Tax | 221.96M |
| Effective Tax Rate | 0.2 |
Stock Price Statistics
The stock price has increased by -21.72% in the last 52 weeks. The beta is 1.39, so IDEXX Laboratories's price volatility has been higher than the market average.
| Beta | 1.39 |
| 52-Week Price Change | -21.72% |
| 50-Day Moving Average | 436.89 |
| 200-Day Moving Average | 456.86 |
| Relative Strength Index (RSI) | 45.42 |
| Average Volume (20 Days) | 709.51K |
Income Statement
In the last 12 months, IDEXX Laboratories had revenue of 3.9B and earned 887.87M in profits. Earnings per share was 10.79.
| Revenue | 3.9B |
| Gross Profit | 2.38B |
| Operating Income | 1.13B |
| Net Income | 887.87M |
| EBITDA | 1.27B |
| EBIT | 1.13B |
| Earnings Per Share (EPS) | 10.79 |
Balance Sheet
The company has 288.27M in cash and 265.62M in debt, giving a net cash position of 22.64M.
| Cash & Cash Equivalents | 288.27M |
| Total Debt | 265.62M |
| Net Cash | 22.64M |
| Retained Earnings | 5.33B |
| Total Assets | 3.29B |
| Working Capital | 331.98M |
Cash Flow
In the last 12 months, operating cash flow was 929M and capital expenditures -130.92M, giving a free cash flow of 798.08M.
| Operating Cash Flow | 929M |
| Capital Expenditures | -130.92M |
| Free Cash Flow | 798.08M |
| FCF Per Share | 9.7 |
Margins
Gross margin is 61.04%, with operating and profit margins of 28.95% and 22.78%.
| Gross Margin | 61.04% |
| Operating Margin | 28.95% |
| Pretax Margin | 28.48% |
| Profit Margin | 22.78% |
| EBITDA Margin | 32.61% |
| EBIT Margin | 28.95% |
| FCF Margin | 20.48% |
Dividends & Yields
IDXX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 2.55% |
| FCF Yield | 2.32% |
Analyst Forecast
The average price target for IDXX is $527.5, which is 24.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $527.5 |
| Price Target Difference | 24.8% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Jun 16, 2015. It was a forward split with a ratio of 2:1.
| Last Split Date | Jun 16, 2015 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 14.43 |
| Piotroski F-Score | 7 |